China Human Vaccine Industry Report, 2020-2026
  • Jul.2020
  • Hard Copy
  • USD $3,400
  • Pages:213
  • Single User License
    (PDF Unprintable)       
  • USD $3,200
  • Code: ZLC111
  • Enterprise-wide License
    (PDF Printable & Editable)       
  • USD $4,800
  • Hard Copy + Single User License
  • USD $3,600
      

In China, the lot release for human vaccines plunged by 17.7% in 2018 when the production record fraud of rabies vaccines for human use, freeze-dried by Changsheng Bio-Technology was exposed. The impact fades away amid tighter control on human vaccines in China. In 2019, National Institutes for Food and Drug Control (NIFDC) approved 570 million doses of human vaccine with a year-on-year increase of 5.4%, among which there was more lot release volume of diphtheria, tetanus and acellular pertussis combined vaccine (adsorbed), recombinant Hepatitis B vaccine, and rabies vaccine for human use (freeze-dried), together sharing 33.9% of the total.

The Chinese human vaccine market is now occupied by local companies, where the state-owned enterprises command more than a half of the market. In the first half of 2020, the players had more lot releases, such as China National Biotec Group (CNBG), Institute of Medical Biology, Chinese Academy of Medical Sciences, Walvax Biotechnology, Amy Biotech & Vaccine, Liaoning Cheng Da, NCPC GeneTech Biotechnology, and Sinovac Biotech, holding a combined 82.2% of the total. Noticeably, CNBG takes a lion’s share 43.3%, leading the pack in the industry.

Although the Chinese human vaccine market is ruled by local companies, the imported vaccines are largely the extra EPI vaccines (not free, and residents can choose whether they want to be inoculated) such as 13-valent pneumonia vaccine, HPV vaccine and DTaP-IPV/Hib vaccine. Yet, the 13-valent pneumonia vaccine of Walvax Biotechnology and the 2-valent pneumonia vaccine of Xiamen Innovax Biotech are approved successively for general availability in the market, challenging the overseas vaccine giants at their games and scrambling for more market shares by price advantage, accompanied by the to-be-soon-launched vaccines like 13-valent pneumonia vaccine of Shenzhen Kangtai Biological Products Co., Ltd., 2-valent/9-valent HPV vaccines of Walvax Biotechnology, 4-valent influenza vaccine and 15-valent pneumonia vaccine of Chongqing Zhifei Biological Products Co., Ltd.

human vaccine_副本.png

The devastating COVID-19 in more than 100 countries causes a total of over 14.77 million cases infected and approximately 609,000 deaths. The mortality rate is high up to 4.1% and the overriding research about coronavirus vaccine and clinical trials get under way.

In at least 200 coronavirus vaccine programs worldwide to date, China stays ahead temporarily in the R&D progress. Seven coronavirus vaccines are in the clinical phase, and Ad5-nCoV, an adenovirus vaccine being co-developed by CanSino Biologics, Inc. and the team led by the academician Chen Wei at the Biological Engineering Institute of Academy of Military Medical Sciences, is advancing faster as its phase-III clinical trials are in place. To curb the pandemic, the related authorities of China will accelerate the examination and approval process for a shorter development cycle and a faster launch to save lives.

Highlights of this report:
20120114.gifHuman vaccine industry in China (environments, status quo, market demand, market size, import & export, competition pattern);
20120114.gifHuman vaccine market segments in China (market demand, lot releases, competitive landscape);
20120114.gif22 human vaccine companies (operation, vaccine business, etc.);
20120114.gifConclusions and development tendencies.

1. Overview of Vaccine Industry
1.1 Definition & Classification
1.2 Industry Chain

2. China Human Vaccine Industry
2.1 Operating Environment
2.1.1 International Market
2.1.2 Policy Environment
2.1.3 Biopharmaceutical Market
2.2 Status Quo
2.3 Market Demand
2.4 Circulation Channels
2.5 Market Size
2.6 Import & Export
2.6.1 Import
2.6.2 Export
2.6.3 Average Price
2.7 Competition Pattern

3. Human Vaccine Market Segments in China
3.1 Hepatitis B Vaccine
3.1.1 Demand
3.1.2 Lot Release Volume
3.1.3 Competition Pattern
3.2 Meningococcal Vaccine
3.2.1 Demand
3.2.2 Lot Release Volume
3.2.3 Competition Pattern
3.2.4 Development Prospect
3.3 Hepatitis A Vaccine
3.3.1 Demand
3.3.2 Lot Release Volume
3.3.3 Competition Pattern
3.4 Influenza Vaccine
3.4.1 Demand
3.4.2 Lot Release Volume
3.4.3 Competition Pattern
3.4.4 Development Trend
3.5 Hib Vaccine
3.5.1 Demand
3.5.2 Lot Release Volume
3.5.3 Competition Pattern
3.5.4 Development Trend
3.6 Human Rabies Vaccine
3.6.1 Demand
3.6.2 Lot Release Volume
3.6.3 Competition Pattern
3.6.4 Development Trend
3.7 Varicella Vaccine
3.7.1 Demand
3.7.2 Lot Release Volume
3.7.3 Competition Pattern
3.7.4 Development Trend
3.8 Pneumococcal Vaccines
3.8.1 Demand
3.8.2 Lot Release Volume
3.8.3 Competition Pattern
3.8.4 Development Trend
3.9 DTP Vaccine
3.9.1 Demand
3.9.2 Lot Release Volume
3.9.3 Competition Pattern
3.9.4 Development Trend
3.10 Poliomyelitis Vaccine
3.10.1 Demand
3.10.2 Lot Release Volume
3.10.3 Competition Pattern
3.10.4 Development Trend
3.11 Hepatitis E Vaccine
3.11.1 Demand
3.11.2 Lot Release Volume
3.11.3 Competition Pattern
3.12 HPV Vaccine 
3.12.1 Status Quo
3.12.2 Lot Release Volume
3.12.3 Competition Pattern
3.12.4 Development Trend
3.13 Hand, Foot and Mouth Disease (HFMD) Vaccine
3.13.1 Demand
3.13.2 Lot Release Volume
3.13.3 Competition Pattern
3.13.4 Development Trend

4. Major Human Vaccine Manufacturers in China
4.1 China National Biotech Group
4.1.1 Profile
4.1.2 National Vaccine & Serum Institute
4.1.3 Chengdu Institute of Biological Products Co., Ltd.
4.1.4 Shanghai Institute of Biological Products Co., Ltd.
4.1.5 Wuhan Institute of Biological Products Co., Ltd.
4.1.6 Lanzhou Institute of Biological Products Co., Ltd.
4.1.7 Changchun Institute of Biological Products Co., Ltd.
4.1.8 Changchun Keygen Biological Products Co., Ltd.
4.2 Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
4.2.1 Profile
4.2.2 Operation
4.2.3 Revenue Structure
4.2.4 R&D and Investment
4.2.5 Production and Sales
4.2.6 Vaccine Business
4.2.7 Development Strategy
4.3 Hualan Biological Engineering Inc.
4.3.1 Profile
4.3.2 Operation
4.3.3 Revenue Structure
4.3.4 R&D
4.3.5 Vaccine Business
4.3.6 Development Strategy
4.4 Chongqing Zhifei Biological Products Co., Ltd.
4.4.1 Profile
4.4.2 Operation
4.4.3 Revenue Structure
4.4.4 Gross Margin
4.4.5 R&D
4.4.6 Development Dynamics
4.4.7 Development Strategy
4.5 Walvax Biotechnology Co, Ltd.
4.5.1 Profile
4.5.2 Operation
4.5.3 Revenue Structure
4.5.4 Gross Margin
4.5.5 R&D
4.5.6 Vaccine Business
4.5.7 Development Strategy
4.6 Liaoning Cheng Da Co., Ltd.
4.6.1 Profile
4.6.2 Operation
4.6.3 Revenue Structure
4.6.4 Gross Margin
4.6.5 Major Customers
4.6.6 R&D
4.6.7 Development Strategy
4.7 Shenzhen Kangtai Biological Products Co., Ltd.
4.7.1 Profile
4.7.2 Operation
4.7.3 Revenue Structure
4.7.4 Gross Margin
4.7.5 R&D
4.7.6 Development Strategy
4.8 Changsheng Bio-Technology Co., Ltd.
4.8.1 Profile
4.8.2 Operation
4.8.3 Revenue Structure
4.8.4 R&D
4.8.5 Development Dynamics
4.9 Olymvax Biopharmaceuticals Inc.
4.9.1 Profile
4.9.2 Operation
4.9.3 Revenue Structure
4.9.4 Gross Margin
4.9.5 R&D
4.9.6 Vaccine Business
4.9.7 Development Strategy
4.10 Sinovac Biotech Ltd.
4.10.1 Profile
4.10.2 Operation
4.10.3 Revenue Structure
4.10.4 Sinovac Biotech (Beijing)
4.11 Changchun BCHT Biotechnology Co. Ltd.
4.11.1 Profile
4.11.2 Operation
4.11.3 Development Dynamics
4.12 Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd.
4.12.1 Profile
4.12.2 Operation
4.13 Tibet Amy Biotech & Vaccine Group Co., Ltd.
4.13.1 Profile
4.13.2 Vaccine Business
4.13.3 Amy ConVac Biopharmaceutical (Jiangsu) Co., Ltd.
4.13.4 Aimei Hissen Vaccine (Dalian) Co., Ltd.
4.13.5 Aimei Weixin Biopharmaceutical (Zhejiang) Co., Ltd.
4.14 NCPC GeneTech Biotechnology Development Co., Ltd.
4.14.1 Profile
4.14.2 Operation
4.15 Dalian Aleph Biomedical Co., Ltd.
4.15.1 Profile
4.15.2 Vaccine Business
4.16 Beijing Minhai Biotechnology Co., Ltd.
4.16.1 Profile
4.16.2 Operation
4.17 CanSino Biologics
4.17.1 Profile
4.17.2 Operation
4.17.3 R&D and Investment
4.17.4 Development Strategy
4.18 Chengdu Kanghua Biological Products Co., Ltd.
4.18.1 Profile
4.18.2 Operation
4.18.3 Revenue Structure
4.18.4 Gross Margin
4.18.5 R&D
4.19 Other Enterprises
4.19.1 Shenzhen Sanofi Pasteur Biological Products Co., Ltd.
4.19.2 Guangzhou Nuocheng Biological Products

5. Summary and Forecast
5.1 Summary
5.2 Development Trends
5.2.1 Human Vaccine Industry is Increasingly Concentrated
5.2.2 Two-child Policy is in Favor of Human Vaccine Industry Growth
5.2.3 Faster Aging of Population Boosts Human Vaccine Industry
5.2.4 Local Companies Invest More Heavily in Research and Development of Vaccine Products Which are Becoming More Various
5.2.5 Demand for Extra EPI Vaccines Is Growing
5.2.6 Coronavirus Vaccines Will Boom
Classification of Vaccines
Vaccine Industry Chain
Global Human Vaccine Market Size, 2010-2020
Global Human Vaccine Market Size, 2019-2026E
Top 15 Vaccine Products Worldwide by Sales, 2019
Global Vaccine Market Share, 2019
R&D Pipelines of Global Top 4 Vaccine Giants
Main Mergers & Acquisitions in the Vaccine Industry Worldwide, 2005-2020
Revenue of Major Global Vaccine Companies, 2011-2019
Related Policies in China Human Vaccine Industry, 2006-2020
Gross Industrial Output Value of China Biopharmaceutical Industry, 2008-2020
Gross Industrial Output Value of China Biopharmaceutical Industry, 2019-2026E
Immunization Procedures (2020) of National EPI Vaccine for Children
EPI Human Vaccine Varieties in China
Top10 Human Vaccines by Lot Release Volume in China, 2019-2020
Lot Release Volume of Human Vaccine in China, 2013-2020
Main Human Vaccine Varieties and Producers Granted Permit for Lot Release in China, 2020H1
Timeline for Vaccine Blockbusters on Market in China
China Human Vaccine Market Size, 2010-2020
China’s Human Vaccine Import Volume and Value by Country, Jun.-May., 2020
Top 10 Countries/Regions of China Human Vaccine Export, Jun.-May., 2020
Export Volume and Value of Human Vaccine in China, 2010-2020
Average Unit Export/Import Price of Human Vaccine in China, 2010-2020
Lot Release Volume Breakdown of Human Vaccines in China by Nature of Enterprise, 2019
Stratified Comparison between Local Vaccine Companies in China
Human Vaccine Lot Release Volume of Major Vaccine Enterprises in China, 2015-2020
Lot Release Volume Breakdown of Human Vaccines in China by Nature of Enterprise, 2020H1
Lot Release Volume of Human Vaccines in China by Enterprise, 2019
Lot Release Volume of Human Vaccines in China by Enterprise, 2020H1
Vaccine Revenue of Major Human Vaccine Enterprises in China, 2013-2019
Lot Release Volume of Major Hepatitis B Vaccine Companies in China, 2013-2020
Hepatitis B Morbidity and Mortality in China, 2013-2019
Lot Release Volume of Hepatitis B Vaccine in China, 2013-2020
Lot Release Volume of Hepatitis B Vaccine in China by Dosage Form, 2013-2020
Share of Major Hepatitis B Vaccine Companies by Lot Release Volume in China, 2013-2020
Meningitis Morbidity and Mortality in China, 2013-2019
Meningococcal Vaccines Lot Release Volume in China, 2013-2020
Meningococcal Vaccines Lot Release Volume in China by Type, 2013-2020
Lot Release Volume of Major Meningococcal Vaccines Companies in China, 2013-2020
Share of Major Meningococcal Vaccines Companies by Lot Release Volume in China, 2013-2020
R&D Status of Meningococcal Conjugate Vaccine in China
Hepatitis A Morbidity and Mortality in China, 2013-2019
Lot Release Volume of Hepatitis A Vaccine in China, 2013-2020
Lot Release Volume of Major Hepatitis A Vaccine Companies in China, 2013-2020
Share of Major Hepatitis A Vaccine Companies by Lot Release Volume in China, 2013-2020
Influenza Morbidity and Mortality in China, 2013-2019
H7N9 Influenza Morbidity and Mortality in China, 2013-2019
Lot Release Volume of Influenza Vaccine in China, 2013-2020
Lot Release Volume of Major Influenza Vaccine Companies in China, 2013-2019
Share of Major Influenza Vaccine Companies by Lot Release Volume in China, 2013-2019
Influenza Outbreak in China, 2014-2020
Free Influenza Vaccination for Targeted Groups in Some Places of China
R&D of Quadrivalent Influenza Vaccine in China
Lot Release Volume of Hib Vaccine in China, 2013-2020
Lot Release Volume of Major Hib Vaccine Companies in China, 2013-2020
Share of Major Hib Vaccine Companies by Lot Release Volume in China, 2013-2020
Rabies Morbidity and Mortality in China, 2013-2019
Lot Release Volume of Human Rabies Vaccine in China, 2013-2020
Lot Release Volume of Major Human Rabies Vaccine Companies in China, 2013-2020
Share of Major Human Rabies Vaccine Companies by Lot Release Volume in China, 2013-2020
Types of Rabies Vaccines for Human Use Now in China
Progress in R&D of Human Rabies Vaccine (Human Diploid Cell) in China
Lot Release Volume of Varicella Vaccine in China, 2013-2020
Lot Release Volume of Major Varicella Vaccine Companies in China, 2013-2020
Share of Major Varicella Vaccine Companies by Lot Release Volume in China, 2013-2020
R&D of Varicella Vaccine in China
Vaccination Rate for Varicella in China and the Developed Countries
Lot Release Volume of Pneumococcal Vaccines in China, 2013-2020
Lot Release Volume of Major Pneumococcal Vaccines Companies in China, 2013-2020
Share of Major Pneumococcal Vaccine Companies by Lot Release Volume in China, 2013-2020
Global Revenue from 13-valent Pneumococcal Vaccines, 2012-2019
Key Chinese Companies’ Progress in R&D of 13-valent Pneumococcal Polysaccharide Conjugate Vaccine
Key Chinese Companies Progress in R&D of 23-valent Pneumococcal Vaccine
Distribution Graph of National Immunization Program where 13-valent Pneumococcal Vaccine Gets Enlisted Worldwide, 2019
Pertussis Morbidity and Mortality in China, 2012-2019
Neonatal Tetanus Morbidity and Mortality in China, 2012-2019
Lot Release Volume of DTP Vaccine in China, 2013-2020
Lot Release Volume of Major DPT Vaccine Companies in China, 2013-2020
Share of Major DTP Vaccine Companies by Lot Release Volume in China, 2013-2020
DTcP Vaccines Launched or Being Developed in China
Lot Release Volume of Poliomyelitis Vaccine Companies in China, 2013-2020
Share of Major Poliomyelitis Vaccine Companies by Lot Release Volume in China, 2013-2020
R&D of Poliomyelitis Vaccine in China
Lot Release Volume of Poliomyelitis Vaccine in China, 2013-2020
Hepatitis E Morbidity and Mortality in China, 2012-2019
Lot Release Volume of Hepatitis E Vaccine in China, 2013-2020
Lot Release Volume of Major Hepatitis E Vaccine Companies in China, 2013-2020
Global Incidence of Cervical Cancer
Correlation between HPV Virus and Various Diseases
HPV Vaccine Products Worldwide
Lot Release Volume of HPV Vaccine in China, 2017-2020
Global HPV Vaccine Revenue (by Product), 2006-2019
Lot Release Volume of HPV Vaccine in China by Enterprise, 2017-2020
Major HPV Vaccine Developers in China and Their Progress
List of Countries Bringing HPV Vaccine into Vaccination Program (Those in Green Having Done This)
Lot Release Volume of Enterovirus 71 Inactivated Vaccines in China, 2016-2020
Product Comparison between Major Chinese Producers of Enterovirus 71 (EV71) Inactivated Vaccine
Lot Release Volume of Enterovirus 71 Inactivated Vaccines (by Enterprise) in China, 2016-2020
Shares for Lot Release Volume of Enterovirus 71 Inactivated Vaccines (by Enterprise) in China, 2016-2020 
Specifications and Place of Origin of China National Biotech Group’s Main Vaccine Products
Vaccine Varieties of Chengdu Institute of Biological Products
Vaccine Varieties of Shanghai Institute of Biological Products
Revenue and Net Income of Beijing Wantai Biological Pharmacy Enterprise, 2016-2020
Revenue of Beijing Wantai Biological Pharmacy Enterprise by Product, 2016-2019
Revenue of Beijing Wantai Biological Pharmacy Enterprise by Region, 2016-2019
Beijing Wantai Biological Pharmacy Enterprise’s R&D Costs and % of Total Revenue, 2016-2020
Wantai’s Vaccines under Development, as of April 2020
Wantai's Representative Innovative Vaccines
Beijing Wantai Biological Pharmacy Enterprise’s Projects with Funds Raised by IPO
Output and Sales of Beijing Wantai Biological Pharmacy Enterprise by Product, 2016-2019
Hepatitis E Vaccine Capacity, Output and Capacity Utilization of Beijing Wantai Biological Pharmacy Enterprise, 2016-2019
Hepatitis E Vaccine Revenue, Sales Volume and Average Price of Beijing Wantai Biological Pharmacy Enterprise, 2016-2019
Gross Margin of Hepatitis E Vaccine of Beijing Wantai Biological Pharmacy Enterprise, 2016-2019
Revenue and Net Income of Hualan Biological Engineering, 2013-2020
Revenue Breakdown of Hualan Biological Engineering by Sector, 2013-2019
Revenue Structure of Hualan Biological Engineering by Sector, 2013-2019
R&D Costs and % of Total Revenue of Hualan Biological Engineering, 2013-2020
Vaccine Output & Sales Volume, Inventory of Hualan Biological Engineering, 2013-2019
Vaccine Revenue and Percentage of Hualan Biological Engineering, 2013-2019
Vaccine Gross Margin of Hualan Biological Engineering, 2013-2019
Main Products Chongqing Zhifei Biological Products is Selling or Promoting according to Agreements, and Their Purposes
Revenue and Net Income of Zhifei Biological, 2012-2020
Revenue Breakdown of Zhifei Biological by Product, 2014-2019
Lot Release Volume Breakdown of Zhifei Biological by Product, 2014-2019
Revenue Breakdown of Zhifei Biological by Region, 2015-2019
Gross Margin of Zhifei Biological by Product, 2013-2019
R&D Costs and % of Total Revenue of Zhifei Biological, 2012-2020
Projects under Registration Process of Zhifei Biological, as of 2019
Progress of Preclinical Projects of Zhifei Biological by 2019
R&D Projects with Phased Achievements in 2019
Revenue and Net Income of Walvax Biotechnology, 2013-2020
Revenue Breakdown of Walvax Biotechnology by Product, 2015-2019
Revenue Breakdown of Walvax Biotechnology by Region, 2015-2019
Gross Margin of Own Vaccine of Walvax Biotechnology, 2013-2019
R&D Costs and % of Total Revenue of Walvax Biotechnology, 2013-2020
Progress of Walvax Biotechnology’s Projects with Raised Fund, as of 2020Q1
Product Registration and Application Progress of Walvax Biotechnology, by 2020Q1
Progress of Products under Registration Declaration of Walvax Biotechnology, as of 2019
Walvax Biotechnology’s Timeline of R&D and GMP Application of 13-valent Pneumococcal Vaccine
Output & Sales Volume, Inventory of Walvax Biotechnology, 2014-2019
Lot Release Volume of Walvax Biotechnology, 2015-2020
Revenue and Net Income of Liaoning Chengda, 2013-2020
Revenue Breakdown of Liaoning Chengda by Product, 2013-2019
Revenue Structure of Liaoning Chengda by Product, 2013-2019
Gross Margin of Liaoning Chengda, 2013-2019
Liaoning Chengda’s Revenue from Top5 Customers and % of Total Revenue, 2015-2019
R&D Costs and % of Total Revenue of Liaoning Chengda, 2014-2020
Main Products and Their Purposes of Shenzhen Kangtai Biological Products
Capacity, Output & Sales Volume of Shenzhen Kangtai Biological Products, 2013-2017
Revenue and Net Income of Kangtai Biological, 2013-2020
Revenue Breakdown of Kangtai Biological by Product, 2015-2019
Lot Release Volume and Percentage of Kangtai Biological, 2015-2019
Revenue Breakdown of Shenzhen Kangtai Biological Products by Region, 2015-2019
Gross Margin of Shenzhen Kangtai Biological Products, 2013-2020
R&D Costs and % of Total Revenue of Kangtai Biological, 2013-2020
Progress of Ongoing Research Projects of Kangtai Biological, as of 2019
Major Non-equity Investments by Shenzhen Kangtai Biological Products, as of 2019
Revenue and Net Income of Changsheng Bio-technology, 2014-2018
Revenue Breakdown of Changsheng Bio-technology by Product, 2014-2018
Revenue Structure of Changsheng Bio-technology by Product, 2014-2018
Output & Sales Volume, Inventory of Changsheng Bio-technology, 2014-2018
Progress of Ongoing Projects of Changsheng Bio-technology as of the end of 2017
R&D Costs and % of Total Revenue of Changsheng Bio-technology, 2014-2017
Development Course of Olymvax Biopharmaceuticals
Revenue and Net Income of Olymvax Biopharmaceuticals, 2017-2020
Revenue of Olymvax Biopharmaceuticals by Region, 2017-2019
Revenue Breakdown of Olymvax Biopharmaceuticals by Sector, 2017-2019
Gross Margin of Olymvax Biopharmaceuticals, 2017-2020
Olymvax Biopharmaceuticals’s R&D Costs and % of Total Revenue, 2017-2019
Tetanus Vaccine (Adsorbed) Capacity, Output and Capacity Utilization of Olymvax Biopharmaceuticals, 2017-2019
Main Products of Sinovac Biotech
Revenue and Net Income of Sinovac Biotech, 2013-2020
Revenue Breakdown of Sinovac Biotech by Product, 2013-2020
Equity Structure of Sinovac Biotech
Financial Indices of Sinovac Biotech, 2015-2019
Financial Indices of Changchun BCHT Biotechnology, 2014-2019
Vaccine Products of Zhejiang Tianyuan Bio-Pharmaceutical
Equity Structure of Amy Biotech
Major Vaccine Companies of Amy Biotch
Lot Release Volume of Human Vaccines of Amy Biotch, 2018-2019
Financial Indices of NCPC GeneTech Biotechnology Development, 2014-2019
Equity Structure of Dalian Aleph Biomedical
Development Goals of Dalian Aleph Biomedical
Financial Indices of Beijing Minhai Biotechnology, 2015-2020
Milestones of CanSino
Consolidated Income of CanSino Biologics, 2016-2019
R&D Cost of CanSino, 2016-2019
Vaccine Pipelines of CanSino under Research
Revenue and Net Income of Kanghua Biological, 2015-2020
Revenue of Kanghua Biological by Product, 2015-2020
Output, Sales Volume and Sales-output Ratio of Kanghua Biological,2015-2019
Capacity and Capacity Utilization of Kanghua Biological,2015-2019
Gross Margin of Kanghua Biological, 2015-2020
R&D cost of Kanghua Biological, 2015-2020
R&D cost of Kanghua Biological by Project, 2015-2019
IPO Investment Projects of Kanghua Biological, 2019
China’s Vaccine Market Size, 2019-2026E
Number of Newborns in China, 2015-2026E
China’s Population Aged over 60 and % of Total Population, 2009-2025
R&D Investment of Major Vaccine Companies in China, 2013-2019
Main Vaccine Products Being Researched by Companies in China and Their Progress
Comparison between EPI Vaccine and Extra EPI Vaccine in China
Main Chinese Vaccine Companies’ Efforts in Extra EPI Vaccines
Extra EPI Vaccines Paid by Medical Insurance and Financial Subsidy Policies in China by Region
COVID-19 Pandemic Map as of July 21, 2020
Some Mainstream Approaches to Coronavirus Vaccine R&D
Progress in Global R&D of Coronavirus Vaccines
Comparison of Coronavirus Vaccines between CanSino Bilogics and Moderna

China Contract Research Organization (CRO) Industry Report, 2020-2026

The contract research organization (CRO) industry has been galloping amid the global pharmaceutical market steadily in head way, the vibrant financing in the medical and health sector, and the prolife...

China Human Vaccine Industry Report, 2020-2026

In China, the lot release for human vaccines plunged by 17.7% in 2018 when the production record fraud of rabies vaccines for human use, freeze-dried by Changsheng Bio-Technology was exposed. The impa...

China Pharmaceutical Distribution Industry Report, 2019-2026

The Chinese pharmaceutical distribution market has been expanding steadily over the recent years, being valued at RMB2,330.3 billion in 2019 with a year-on-year increase of 8.9%, of which the pharmace...

China Pharmaceutical Distribution Industry Report, 2019-2025

China’s pharmaceutical distribution industry has sustained steady growth over the years. In 2018, the market was worth RMB2,194.5 billion, a 9.6% rise from RMB2,001.6 billion (up by 8.4% YoY) in 2017,...

China Pharmaceutical Packaging Industry Report, 2019-2025

Being incentivized by the burgeoning pharmaceuticals industry, Chinese pharmaceutical packaging market size sustained growth rates of around 10% in recent years, and outstripped RMB100 billion in 2018...

China Blood Product Industry Report, 2018-2022

The blood product industry in China develops under stimulation of industry policies and downstream demand. The country recorded total lot release volume of 64.11 million bottles of blood products in 2...

China Pharmaceutical Distribution Industry Report, 2017-2021

The Chinese pharmaceutical distribution market has developed steadily but at a slower rate in recent years. The industry rose by 10.4% year on year to RMB1.8393 trillion in 2016 and is expected to hit...

China Blood Product Industry Report, 2017-2021

China’s blood product market size mushroomed in 2016 under the impetus of liberalization of limited-price policy, price rises in varying degrees and lot release volume growth for blood products in 201...

China Pharmaceutical Packaging Industry Report, 2016-2021

Under the impetus of the fast-growing downstream pharmaceutical industry, Chinese pharmaceutical packaging market size increased year by year at the CAGR of 11.2% during 2010-2016. From 2017 to 2021, ...

China Pharmaceutical Glass Packaging Industry Report, 2014-2017

In recent years, advances in new healthcare reform have boosted market demand from China pharmaceuticals industryand driven growth in the demand from pharmaceutical packaging industry. In 2014, the Ch...

China Vitamin Industry Report,2014-2017

China is the world's largest production base of vitamins, with vitamin C and vitamin E as its most important products, wherein vitamin C and related products account for more than 60% of its total out...

China Chemical Pharmaceutical Industry Report, 2013-2016

Chemical pharmaceutical consists mainly of chemical drug preparation and active pharmaceutical ingredient (API), and the gross margin of chemical drug preparation industry is generally higher than tha...

China Pharmaceutical Distribution Industry Report, 2013

Thanks to the continuous advancement in new medical reform, China’s pharmaceutical distribution industry has maintained a fairly rapid growth in recent years, with the sales value showed a CAGR of rou...

China Pharmaceutical Glass Packaging Industry Report, 2013-2016

Influenced by the substitution of plastic, aluminum foil and other new packaging materials as well as the declining packaging material purchase prices incurred by the medical reform, China pharmaceuti...

China Chinese Patent Medicine Industry Report, 2013-2016

Chinese patent medicine refers to the certain dosage forms of medicine, under the guidance of TCM (traditional Chinese medicine) theory, made from traditional Chinese medicinal materials in accordance...

Global and China Insulin Industry Report, 2013-2017

As the third largest human health disease following neoplastic disease, cardiovascular and cerebrovascular diseases, the number of diabetic patients has continued growing from 246 million in 2007 to 3...

China Large Volume Parenteral (LVP) Industry Report, 2013-2015

Under the context of China's medical reform and sustainable development of the pharmaceutical market, the output and demand of Large Volume Parenteral (LVP) which is one of the top five Chinese prepar...

China Vitamin Industry Report, 2012-2015

As a great power of vitamin production and export, China has long been known as the world’s vitamin production base. In recent years, its vitamin exports on external demand accounted for about 80% of ...

2005- www.researchinchina.com All Rights Reserved 京ICP备05069564号-1 京公网安备1101054484号